Table 1.
Relationship between CDK5 expression and clinicopathological features
| Parameters | Total (n) | Expression of CDK5 n (%) | X2 | P | |
|---|---|---|---|---|---|
|
| |||||
| Negative | Positive | ||||
| Tissue | |||||
| Normal tissue | 54 | 36 (66.7%) | 18 (33.3%) | -6.217 | <0.001 |
| NPC | 393 | 99 (25.2%) | 294 (74.8%) | ||
| Histological type | |||||
| Adenocarcinoma | 4 | 0 | 4 (100%) | -1.165 | 0.244 |
| Squamous carcinoma | 389 | 99 (25.4%) | 290 (74.6%) | ||
| Squamous differentiation | |||||
| Differentiated | 250 | 76 (30.4%) | 174 (69.6%) | -3.002 | 0.003 |
| Undifferentiated | 139 | 23 (16.5%) | 116 (83.5%) | ||
| Gender | |||||
| Female | 121 | 28 (23.1%) | 93 (76.9%) | -0.624 | 0.533 |
| Male | 272 | 71 (26.1%) | 201 (73.9%) | ||
| Age | |||||
| ≤50 | 208 | 56 (26.9%) | 152 (73.1%) | -0.838 | 0.402 |
| >50 | 185 | 43 (23.2%) | 142 (76.8%) | ||
| T category | |||||
| T1 | 30 | 17 (56.7%) | 13 (43.3%) | H=22.069a | <0.001 |
| T2 | 32 | 12 (37.5%) | 20 (62.5%) | ||
| T3 | 27 | 2 (7.4%) | 25 (92.6%) | ||
| T4 | 22 | 2 (9.1%) | 20 (90.9%) | ||
| N category | |||||
| N0 | 6 | 4 (66.7%) | 2 (33.3%) | H=14.189a | 0.003 |
| N1 | 22 | 12 (54.5%) | 10 (45.5%) | ||
| N2 | 62 | 14 (22.6%) | 48 (77.4%) | ||
| N3 | 21 | 3 (14.3%) | 18 (85.7%) | ||
| TNM stage | |||||
| I | 6 | 4 (66.7%) | 2 (33.3%) | H=17.750a | <0.001 |
| II | 22 | 12 (54.5%) | 10 (45.5%) | ||
| III | 48 | 14 (29.2%) | 34 (70.8%) | ||
| IV | 35 | 3 (8.6%) | 32 (91.4%) | ||
a
Kruskal-Wallis H test was performed to analyze the difference.
Chi-square test was used in the rest of statistics.